UCB（UCB）株式概要
UCB社はバイオ医薬品会社であり、世界中の神経・免疫疾患患者向けの製品とソリューションを開発している。 詳細
報酬
リスク分析
リスクチェックの結果、UCB 、リスクは検出されなかった。
UCB Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
UCB SA 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €242.00 |
| 52週高値 | €289.50 |
| 52週安値 | €153.10 |
| ベータ | 0.17 |
| 1ヶ月の変化 | 1.26% |
| 3ヶ月変化 | -10.67% |
| 1年変化 | 53.80% |
| 3年間の変化 | 192.98% |
| 5年間の変化 | 216.26% |
| IPOからの変化 | 79,208.90% |
最新ニュース
ナラティブの更新 • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
ナラティブの更新 • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.Recent updates
ナラティブの更新 • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.ナラティブの更新 • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.ナラティブの更新 • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.ナラティブの更新 • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.ナラティブの更新 • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.
ナラティブの更新 • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.ナラティブの更新 • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.ナラティブの更新 • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.ナラティブの更新 • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.ナラティブの更新 • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.ナラティブの更新 • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.ナラティブの更新 • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.ナラティブの更新 • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.分析記事 • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ナラティブの更新 • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.ナラティブの更新 • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.分析記事 • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...ナラティブの更新 • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.ナラティブの更新 • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.ナラティブの更新 • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.分析記事 • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
新しいナラティブ • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.株主還元
| UCB | BE Pharmaceuticals | BE 市場 | |
|---|---|---|---|
| 7D | 5.3% | 2.6% | 2.9% |
| 1Y | 53.8% | 11.5% | 21.4% |
業界別リターン: UCB過去 1 年間で11.5 % の収益を上げたBelgian Pharmaceuticals業界を上回りました。
リターン対市場: UCB過去 1 年間で21.4 % の収益を上げたBelgian市場を上回りました。
価格変動
| UCB volatility | |
|---|---|
| UCB Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in BE Market | 7.0% |
| 10% least volatile stocks in BE Market | 2.6% |
安定した株価: UCB 、 Belgian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: UCBの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1925 | 9,765 | Jean-Christophe Tellier | www.ucb.com |
UCB社はバイオ医薬品会社で、世界中の神経・免疫疾患患者を対象とした製品とソリューションを開発している。同社の主要製品には、炎症性TNF介在性疾患、強直性脊椎炎（AS）、軸索性脊椎関節炎、クローン病、非放射線性軸索性脊椎関節炎、尋常性乾癬、乾癬性関節炎、関節リウマチの治療薬であるCimzia、てんかんの治療薬であるVimpat、Keppra、Briviact、パーキンソン病およびレストレスレッグス症候群の治療薬であるNeuproなどがある。また、てんかん発作群に対する点鼻薬レスキュー治療薬であるNayzilam、アレルギー治療薬であるZyrtecとXyzalも提供している。さらに、閉経後女性の骨粗鬆症治療薬Evenity、尋常性乾癬、関節症性乾癬、汗腺膿瘍、軸性脊椎関節炎治療薬Bimzelx、Dravet/Lennox-Gastaut症候群治療薬Fintepla、重症筋無力症治療薬RYSTIGGOとZILBRYSQも提供している。さらに、TK2欠損症治療薬ドキセシチン／ドキシリブチミン、CDKL5欠損症治療薬フェンフルラミン、全身性エリテマトーデス治療薬ダピロリズマブペゴル、定型遷延性発作治療薬スタッカートアルプラゾラム、アルツハイマー病治療薬ベプラネマブ、パーキンソン病治療薬UCB0222、アトピー性皮膚炎治療薬UCB9741およびUCB1381を開発している。また、受託製造も行っている。同社は1925年に設立され、ベルギーのブリュッセルに本社を置いている。
UCB SA 基礎のまとめ
| UCB 基礎統計学 | |
|---|---|
| 時価総額 | €46.07b |
| 収益（TTM） | €1.56b |
| 売上高(TTM) | €7.74b |
29.6x
PER（株価収益率6.0x
P/SレシオUCB は割高か？
公正価値と評価分析を参照収益と収入
| UCB 損益計算書（TTM） | |
|---|---|
| 収益 | €7.74b |
| 売上原価 | €1.99b |
| 売上総利益 | €5.75b |
| その他の費用 | €4.19b |
| 収益 | €1.56b |
直近の収益報告
Dec 31, 2025
次回決算日
Jul 30, 2026
| 一株当たり利益（EPS） | 8.18 |
| グロス・マージン | 74.29% |
| 純利益率 | 20.13% |
| 有利子負債／自己資本比率 | 19.0% |
UCB の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.6%
現在の配当利回り18%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 14:33 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
UCB SA 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。40
| アナリスト | 機関 |
|---|---|
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |
| Charles Pitman | Barclays |